Plain-English translation of NCT06557369 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called reSEES, which uses a combination of light therapy to help slow the progression of intermediate age-related macular degeneration (AMD) — a common eye condition that affects central vision as people age. About 30 patients will receive this treatment on one eye while their other eye serves as a control to help researchers see whether the treatment is working. The study will follow participants for one year to measure safety and whether the treatment slows vision loss.
Intermediate AMD is a stage of vision loss that can gradually worsen and lead to more serious eye disease. Right now, there are limited treatment options to slow this progression, so researchers are testing this new light-based approach to see if it can help prevent or delay further vision loss in patients with this condition.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the light therapy treatment on your worse eye (or left eye) while your other eye remains untreated as a comparison. You will visit the clinic 10 times over 52 weeks for eye exams at specific timepoints (days 3, 10, 17, and weeks 18, 24, and 52). At each visit, researchers will examine your eyes, check for any side effects, and measure how your vision is responding to treatment using imaging and vision tests. The study will also ask about your mood, general well-being, and how you're managing with your vision.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy